Annual Total Liabilities
$133.62 M
+$3.28 M+2.52%
December 1, 2024
Summary
- As of March 13, 2025, CCCC annual total liabilities is $133.62 million, with the most recent change of +$3.28 million (+2.52%) on December 1, 2024.
- During the last 3 years, CCCC annual total liabilities has risen by +$16.46 million (+14.05%).
- CCCC annual total liabilities is now -41.96% below its all-time high of $230.22 million, reached on December 31, 2019.
Performance
CCCC Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$133.62 M
+$212.00 K+0.16%
December 31, 2024
Summary
- As of March 13, 2025, CCCC quarterly total liabilities is $133.62 million, with the most recent change of +$212.00 thousand (+0.16%) on December 31, 2024.
- Over the past year, CCCC quarterly total liabilities has increased by +$212.00 thousand (+0.16%).
- CCCC quarterly total liabilities is now -65.30% below its all-time high of $385.05 million, reached on September 30, 2020.
Performance
CCCC Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
CCCC Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2.5% | +0.2% |
| 3 y3 years | +14.1% | +0.2% |
| 5 y5 years | -42.0% | +0.2% |
CCCC Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -5.6% | +14.1% | -11.5% | +14.2% |
| 5 y | 5-year | -42.0% | +14.1% | -65.3% | +22.4% |
| alltime | all time | -42.0% | +14.1% | -65.3% | +22.4% |
C4 Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $133.62 M(+0.2%) |
| Dec 2024 | $133.62 M(+2.5%) | - |
| Sep 2024 | - | $133.40 M(-0.5%) |
| Jun 2024 | - | $134.03 M(-4.3%) |
| Mar 2024 | - | $140.09 M(+7.5%) |
| Dec 2023 | $130.34 M(-8.0%) | $130.34 M(+11.4%) |
| Sep 2023 | - | $116.99 M(-17.2%) |
| Jun 2023 | - | $141.30 M(+5.8%) |
| Mar 2023 | - | $133.57 M(-5.7%) |
| Dec 2022 | $141.61 M | $141.61 M(-1.2%) |
| Sep 2022 | - | $143.26 M(-3.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $147.88 M(-2.0%) |
| Mar 2022 | - | $150.96 M(+28.8%) |
| Dec 2021 | $117.16 M(-1.8%) | $117.16 M(+7.4%) |
| Sep 2021 | - | $109.13 M(-2.6%) |
| Jun 2021 | - | $111.99 M(+1.5%) |
| Mar 2021 | - | $110.30 M(-7.6%) |
| Dec 2020 | $119.35 M(-48.2%) | $119.35 M(-69.0%) |
| Sep 2020 | - | $385.05 M(+209.8%) |
| Jun 2020 | - | $124.29 M(-46.0%) |
| Dec 2019 | $230.22 M(+1.8%) | $230.22 M |
| Dec 2018 | $226.24 M | - |
FAQ
- What is C4 Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for C4 Therapeutics?
- What is C4 Therapeutics annual total liabilities year-on-year change?
- What is C4 Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for C4 Therapeutics?
- What is C4 Therapeutics quarterly total liabilities year-on-year change?
What is C4 Therapeutics annual total liabilities?
The current annual total liabilities of CCCC is $133.62 M
What is the all time high annual total liabilities for C4 Therapeutics?
C4 Therapeutics all-time high annual total liabilities is $230.22 M
What is C4 Therapeutics annual total liabilities year-on-year change?
Over the past year, CCCC annual total liabilities has changed by +$3.28 M (+2.52%)
What is C4 Therapeutics quarterly total liabilities?
The current quarterly total liabilities of CCCC is $133.62 M
What is the all time high quarterly total liabilities for C4 Therapeutics?
C4 Therapeutics all-time high quarterly total liabilities is $385.05 M
What is C4 Therapeutics quarterly total liabilities year-on-year change?
Over the past year, CCCC quarterly total liabilities has changed by +$212.00 K (+0.16%)